搜尋結果
4 天前 · Share. MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4 ...
2024年5月6日 · BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific ...
2024年5月6日 · Continued development and commercial preparation for a 2024 season variant-adapted COVID-19 vaccine. First quarter 2024 revenues of €187.6 million, net loss of €315.1 million and loss per share of €1.31 ($1.421) Maintained strong financial position with €16.9 billion in cash, cash equivalents and security investments.
2024年5月13日 · BioNTech : Corporate Presentation. May 13, 2024 at 04:58 pm EDT. Corporate Presentation. May 2024. This Slide Presentation Includes Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements ...
2024年5月6日 · BioNTech says 90% of 2024 revenues will accrue at end of year. May 06, 2024 at 07:03 am EDT. FRANKFURT (Reuters) -Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year.
2024年5月3日 · MT. BioNTech : Report of the Management Board on Agenda Items 12 and 13 lit. c) and d) May 02, 2024 at 08:23 pm EDT. English Convenience Translation - the German language is decisive. Annual General Meeting of BioNTech SE on 17 May 2024. Report of the Management Board on Agenda Item 12 (Amendment of authorizations to issue share options) and on ...
2024年5月15日 · WASHINGTON, May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with moti...
